Sai Life Sciences (NSE:SAILIFE) ROCE %: 21.06% (As of Mar. 2026)


NSE:SAILIFE Sai Life Sciences Ltd NSE:SAILIFE
18 GF Score
Price ₹1,221.30
! 4 Warning Signs
View Full Analysis

What is Sai Life Sciences ROCE %?

Sai Life Sciences NSE:SAILIFE +1.35% 18 ROCE % is 21.06% as of Mar. 2026. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sai Life Sciences's annualized ROCE % for the quarter that ended in Mar. 2026 was 21.06%.

Sai Life Sciences  (NSE:SAILIFE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sai Life Sciences ROCE % Related Terms

Sai Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Sai Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences ROCE % Chart

Sai Life Sciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
4.09 6.50 13.17 15.34 19.37

Sai Life Sciences Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.37 15.34 19.00 22.51 21.06
NSE:SAILIFE
18GF Score
Sai Life Sciences Ltd NSE:SAILIFE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Life Sciences ROCE % Calculation

Sai Life Sciences's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=5054.31/( ( (31599.75 - 7324.9) + (36261.4 - 8336.78) )/ 2 )
=5054.31/( (24274.85+27924.62)/ 2 )
=5054.31/26099.735
=19.37 %

Sai Life Sciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=5882.08/( ( (0 - 0) + (36261.4 - 8336.78) )/ 1 )
=5882.08/( ( 0 + 27924.62 )/ 1 )
=5882.08/27924.62
=21.06 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 21.06% mean?
Sai Life Sciences (NSE:SAILIFE) has a ROCE % of 21.06% as of Mar. 2026.
Is Sai Life Sciences' ROCE % too high?
Sai Life Sciences' current ROCE % is 21.06%. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' ROCE % compare to TMO and DHR?
Sai Life Sciences' ROCE % of 21.06% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Sai Life Sciences's current ROCE % is 21.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current ROCE % of 21.06%. The current ROCE % is 21.06%. Sai Life Sciences' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current ROCE % is 21.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Life Sciences Business Description

Other Exchanges 544306:India
Address Gachibowli Miyapur Road, L4- 01 & 02, SLN Terminus Survey, Survey no. 133, Gachibowli, Hyderabad, TG, IND, 500032
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score

Get the complete analysis for NSE:SAILIFE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,221.30
Price